Labetuzumab govitecan
Modify Date: 2024-04-06 16:46:57
Labetuzumab govitecan structure
|
Common Name | Labetuzumab govitecan | ||
|---|---|---|---|---|
| CAS Number | 1469876-18-3 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Labetuzumab govitecanLabetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer[1][2][3]. |
| Name | Labetuzumab govitecan |
|---|
| Description | Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vivo | Labetuzumab govitecan (总共 1.0 mg，腹腔注射) 可延长 GW-39 肺转移小鼠模型的中位生存期[2]。 Labetuzumab govitecan (25 mg/kg，腹腔注射，每周两次，持续 4 周) 可延长皮下 LS174T 异种移植裸鼠的中位生存期[2]。 Animal Model: sc LS174T Xenograft in nude mice Dosage: 25 mg/kg Administration: i.p. twice weekly for 4 weeks Result: Prolonged median survival. Animal Model: LS174T tumor xenograft model in nude mice (PK assay) Dosage: 0.25 mg Administration: i.v. Result: T1/2: 112.5 h; Cmax: 115 μg/mL; MRT: 147 h. |
| References |
| No Any Chemical & Physical Properties |